## Index of Drug Names

Note: page numbers in italics refer to figures and tables

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>acamprosate</td>
<td>102, 244–8</td>
</tr>
<tr>
<td>acetalaminophen</td>
<td>95, 421–2</td>
</tr>
<tr>
<td>N-acetylcysteine</td>
<td>42</td>
</tr>
<tr>
<td>Aderna (L-D-amphetamine)</td>
<td>155–6, 159, 160, 271–2</td>
</tr>
<tr>
<td>Adriaycin</td>
<td>223–4</td>
</tr>
<tr>
<td>Allegra (fexofenidine)</td>
<td>95–6</td>
</tr>
<tr>
<td>alprazolam</td>
<td>1, 47, 292, 294–9, 316, 328, 406, 425–6</td>
</tr>
<tr>
<td>amantadine</td>
<td>317–18</td>
</tr>
<tr>
<td>amisulpride</td>
<td>130–1</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>315–17, 319–20</td>
</tr>
<tr>
<td>amoxapine</td>
<td>260–4</td>
</tr>
<tr>
<td>anfimphetamine XR</td>
<td>155, 156, 159–60, 271–2</td>
</tr>
<tr>
<td>Ananga (clozapine)</td>
<td>36–7, 41, 42, 410</td>
</tr>
<tr>
<td>angel dust (phenycyclidine)</td>
<td>209, 211–12</td>
</tr>
<tr>
<td>Antabuse (disulfiram)</td>
<td>244–5, 248</td>
</tr>
<tr>
<td>Artane (trihexyphenidyl)</td>
<td>35, 37–8</td>
</tr>
<tr>
<td>Asendin (amoxapine)</td>
<td>260–4</td>
</tr>
<tr>
<td>aspirin</td>
<td>169, 328</td>
</tr>
<tr>
<td>atomoxetine</td>
<td>138–9, 156–8, 227, 229–31</td>
</tr>
<tr>
<td>Aurox (moclobemide)</td>
<td>8, 113</td>
</tr>
<tr>
<td>Azilene (rasiligine)</td>
<td>8, 113</td>
</tr>
<tr>
<td>azulfidine</td>
<td>421–2</td>
</tr>
<tr>
<td>benztrpine</td>
<td>279–80, 283–5</td>
</tr>
<tr>
<td>botulinum toxin</td>
<td>284–5</td>
</tr>
<tr>
<td>buspirone</td>
<td>4, 5, 36–7, 42, 176, 323–4</td>
</tr>
<tr>
<td>Cafergot (ergotamine)</td>
<td>95–6</td>
</tr>
<tr>
<td>California rocket fuel</td>
<td>300, 326, 328</td>
</tr>
<tr>
<td>Camprol (acamprosate)</td>
<td>102, 244–8</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>10, 18–19, 108, 258–9, 293–4, 342, 344–8, 452</td>
</tr>
<tr>
<td>carbidopa</td>
<td>317</td>
</tr>
<tr>
<td>Celexa (citalopram)</td>
<td>29, 36–7, 42, 169, 172, 186, 201, 206, 319–20, 352–3</td>
</tr>
<tr>
<td>cimetidine</td>
<td>257–8</td>
</tr>
<tr>
<td>Ciprilex (escitalopram)</td>
<td>42, 83, 85, 117, 201–2, 205–6, 243–4, 335–6, 352–4</td>
</tr>
<tr>
<td>citrozine</td>
<td>95–6</td>
</tr>
<tr>
<td>clomipramine</td>
<td>36–7, 41, 42, 410</td>
</tr>
</tbody>
</table>
Index of Drug Names

Cogentin (benztropine)  279–80, 283–5
Concerta (methylphenidate)  10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 156–8, 160, 168–9, 229, 244–6, 271, 387
Consta (risperidone)  309–13
coumadin  27
cyclobenzaprine  10, 95–6
cymbalta (duloxetine)  3, 5–6, 140–1
Cogan (benztropine)  279–80, 283–5
Concerta (methylphenidate)  10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 156–160, 168–9, 229, 244–6, 271, 387
Consta (risperidone)  309–13
coumadin  27
cyclobenzaprine  10, 95–6
cymbalta (duloxetine)  3, 5–6, 140–1
Cogan (benztropine)  279–80, 283–5
Concerta (methylphenidate)  10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 156–160, 168–9, 229, 244–6, 271, 387
Consta (risperidone)  309–13
coumadin  27
cyclobenzaprine  10, 95–6
cymbalta (duloxetine)  3, 5–6, 140–1
Cogan (benztropine)  279–80, 283–5
Concerta (methylphenidate)  10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 156–160, 168–9, 229, 244–6, 271, 387
Consta (risperidone)  309–13
coumadin  27

donepezil  226–7, 229–31, 458
doxazosin  27
doxepin  102, 243–4
Elavil (amitriptyline)  315–17, 319–20
Eldepryl (selegiline oral)  8, 27
Embral (etanercept)  423
Emtrase (selegiline transdermal system)  6, 8, 53–5, 110–112, 113
ephephrine  10
erogota mine  95–6
escalitomar (22, 83, 85, 117, 201–2, 205–6, 243–4, 335–6, 352–4
estrogen/progesterone  316
eszopiclone  366–7, 420–5
etanercept  423
Faverin (fluvoxamine)  42, 129–31, 176–8, 201–2, 206, 352–3, 387
Feldene (piroxicam)  95–6
fexofenidine  95–6
flexeril (clobenapzarine)  10, 95–6
fluphenazine  210
fluvoxamine  42, 129–31, 176–8, 201–2, 206, 352–3, 387
fagabentin  27, 29, 35, 37–8, 48–9, 51, 53–5, 102, 108, 258–9, 293–4, 418
galantamine  123–14
glucophage  410
glucotrol  410
guanfacine XR  138–42
Haldol (haloperidol)  21, 117–18, 130, 210, 238, 258–9, 260–5, 310–11, 452
### Index of Drug Names

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>haloperidol</td>
<td>21, 117–18, 130, 210, 238, 258–65, 310–11, 452</td>
</tr>
<tr>
<td>Humira (adalimumab)</td>
<td>423</td>
</tr>
<tr>
<td>hydrocodone</td>
<td>298–9, 417–19, 421–2, 424–6</td>
</tr>
<tr>
<td>hydrocodone + acetaminophen</td>
<td>95–6, 242</td>
</tr>
<tr>
<td>ibuprofen</td>
<td>421–2, 424–6</td>
</tr>
<tr>
<td>imuran</td>
<td>27</td>
</tr>
<tr>
<td>Inderal (propranolol)</td>
<td>238, 345–7</td>
</tr>
<tr>
<td>Intuniv (guanfacine XR)</td>
<td>138–42</td>
</tr>
<tr>
<td>isocarboxazid</td>
<td>8, 113</td>
</tr>
<tr>
<td>isometheptene mucate</td>
<td>95</td>
</tr>
<tr>
<td>isradipine</td>
<td>106</td>
</tr>
<tr>
<td>Keppra (leviracetam)</td>
<td>108, 213–14, 293–4</td>
</tr>
<tr>
<td>ketamine</td>
<td>325–6, 333</td>
</tr>
<tr>
<td>Lanoxtin</td>
<td>27</td>
</tr>
<tr>
<td>leflunomide</td>
<td>424–5</td>
</tr>
<tr>
<td>levitiracetam</td>
<td>108, 213–14, 293–4</td>
</tr>
<tr>
<td>levodopa</td>
<td>317</td>
</tr>
<tr>
<td>levothryoxine</td>
<td>238, 410</td>
</tr>
<tr>
<td>Levrox (fluvoxamine)</td>
<td>42, 129–31, 176–8, 201–2, 206, 352–3, 387</td>
</tr>
<tr>
<td>Lexapro (escitalopram)</td>
<td>42, 83, 85, 117, 201–2, 205–6, 243–4, 335–6, 352–4</td>
</tr>
<tr>
<td>lisdexamfetamine</td>
<td>138–41, 156–8</td>
</tr>
<tr>
<td>lisinopril</td>
<td>35, 37–8</td>
</tr>
<tr>
<td>lorcarin</td>
<td>345</td>
</tr>
<tr>
<td>loxapine</td>
<td>210, 212–14, 260–4, 292–8</td>
</tr>
<tr>
<td>Loxitane (loxapine)</td>
<td>210, 212–14, 260–4, 292–8</td>
</tr>
<tr>
<td>Luvox (fluvoxamine)</td>
<td>42, 129–31, 176–8, 201–2, 206, 352–3, 387</td>
</tr>
<tr>
<td>Lyrica (pregabaline)</td>
<td>53–5, 102, 108, 293–4, 420–2, 425–6</td>
</tr>
<tr>
<td>Manerix (moclobemide)</td>
<td>8, 113</td>
</tr>
<tr>
<td>marijuana, medical</td>
<td>426–7</td>
</tr>
<tr>
<td>Marplan (isocarboxazid)</td>
<td>8, 113</td>
</tr>
<tr>
<td>medoxomil</td>
<td>106</td>
</tr>
<tr>
<td>memantine</td>
<td>227, 442–3</td>
</tr>
<tr>
<td>meperidine</td>
<td>10</td>
</tr>
<tr>
<td>metformin</td>
<td>35, 37–8, 344–5</td>
</tr>
<tr>
<td>methadone</td>
<td>10</td>
</tr>
<tr>
<td>methamphetamine</td>
<td>246–7</td>
</tr>
<tr>
<td>methotrexate</td>
<td>421–2</td>
</tr>
<tr>
<td>L-methylfolate</td>
<td>5, 323–4</td>
</tr>
<tr>
<td>methylphenidate</td>
<td>10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 160, 168–9, 229, 244–6, 387</td>
</tr>
<tr>
<td>methylphenidate extended release</td>
<td>53</td>
</tr>
<tr>
<td>methylphenidate ORS</td>
<td>156–8</td>
</tr>
<tr>
<td>methylphenidate transdermal patch</td>
<td>138–9</td>
</tr>
<tr>
<td>d-methylphenidate XR</td>
<td>156–8</td>
</tr>
<tr>
<td>d,l-methylphenidate</td>
<td>271</td>
</tr>
<tr>
<td>metoprolol</td>
<td>106</td>
</tr>
<tr>
<td>mexiteline</td>
<td>420–1</td>
</tr>
<tr>
<td>Mifrin (isometheptene mucate)</td>
<td>95</td>
</tr>
<tr>
<td>milnacipran</td>
<td>420–1, 426–7</td>
</tr>
<tr>
<td>Minipress (prazosin)</td>
<td>95–6, 102</td>
</tr>
<tr>
<td>Miraex (pramipexole)</td>
<td>48–9, 50–1, 442–3</td>
</tr>
<tr>
<td>mirtazapine</td>
<td>5–6, 42, 53–5, 66–7, 102, 109, 171, 262–4, 293–300, 317–18, 323–4, 328, 410</td>
</tr>
<tr>
<td>Membran (isocarboxazid)</td>
<td>8, 113</td>
</tr>
<tr>
<td>memantine</td>
<td>227, 442–3</td>
</tr>
<tr>
<td>meperidine</td>
<td>10</td>
</tr>
<tr>
<td>metformin</td>
<td>35, 37–8, 344–5</td>
</tr>
<tr>
<td>methadone</td>
<td>10</td>
</tr>
<tr>
<td>methamphetamine</td>
<td>246–7</td>
</tr>
<tr>
<td>methotrexate</td>
<td>421–2</td>
</tr>
<tr>
<td>L-methylfolate</td>
<td>5, 323–4</td>
</tr>
<tr>
<td>methylphenidate</td>
<td>10, 48–9, 50, 53–5, 70–5, 136–7, 139–40, 160, 168–9, 229, 244–6, 387</td>
</tr>
<tr>
<td>methylphenidate extended release</td>
<td>53</td>
</tr>
<tr>
<td>methylphenidate ORS</td>
<td>156–8</td>
</tr>
<tr>
<td>methylphenidate transdermal patch</td>
<td>138–9</td>
</tr>
<tr>
<td>d-methylphenidate XR</td>
<td>156–8</td>
</tr>
<tr>
<td>d,l-methylphenidate</td>
<td>271</td>
</tr>
<tr>
<td>metoprolol</td>
<td>106</td>
</tr>
<tr>
<td>mexiteline</td>
<td>420–1</td>
</tr>
<tr>
<td>Mifrin (isometheptene mucate)</td>
<td>95</td>
</tr>
<tr>
<td>milnacipran</td>
<td>420–1, 426–7</td>
</tr>
<tr>
<td>Minipress (prazosin)</td>
<td>95–6, 102</td>
</tr>
<tr>
<td>Miraex (pramipexole)</td>
<td>48–9, 50–1, 442–3</td>
</tr>
<tr>
<td>mirtazapine</td>
<td>5–6, 42, 53–5, 66–7, 102, 109, 171, 262–4, 293–300, 317–18, 323–4, 328, 410</td>
</tr>
</tbody>
</table>
## Index of Drug Names

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>moclobemide</td>
<td>8, 113</td>
</tr>
<tr>
<td>modafinil</td>
<td>171, 189–90, 227–31, 238, 262–4, 410, 420–2, 424–6, 439–40</td>
</tr>
<tr>
<td>N-acetylcysteine</td>
<td>42</td>
</tr>
<tr>
<td>naltrexone</td>
<td>102, 250, 344, 345</td>
</tr>
<tr>
<td>naltrexone 30 day injection</td>
<td>244–8</td>
</tr>
<tr>
<td>naltrexone oral</td>
<td>244–5, 268, 250</td>
</tr>
<tr>
<td>Nardil (phenelzine)</td>
<td>8, 113, 42, 186, 323–4, 410</td>
</tr>
<tr>
<td>Navane (thiothixene)</td>
<td>210</td>
</tr>
<tr>
<td>nefazodone</td>
<td>210, 262–4, 292</td>
</tr>
<tr>
<td>Norpramin (desipramine)</td>
<td>292</td>
</tr>
<tr>
<td>nortriptyline</td>
<td>171, 189–16, 323–5</td>
</tr>
<tr>
<td>Nuvigil (armodafinil)</td>
<td>171</td>
</tr>
<tr>
<td>olanzapine–flupoxetine combination</td>
<td>246–7</td>
</tr>
<tr>
<td>olmesartin</td>
<td>106</td>
</tr>
<tr>
<td>oxcarbazepine</td>
<td>70–1, 108, 293–4, 342, 345–7</td>
</tr>
<tr>
<td>oxycodone</td>
<td>95–6, 420–2, 424–6</td>
</tr>
<tr>
<td>Oxycontin (oxycodone)</td>
<td>95–6, 420–2, 424–6</td>
</tr>
<tr>
<td>Pamelor (nortriptyline)</td>
<td>186, 315–16, 323–5</td>
</tr>
<tr>
<td>Parnate (tranylcypromine)</td>
<td>8, 112, 113, 186</td>
</tr>
<tr>
<td>Paxil (paroxetine)</td>
<td>2, 33, 35, 37–8, 42, 44, 102, 176–8, 201–2, 243–4, 291–2, 315–16, 342, 352–3, 401, 438–40, 442</td>
</tr>
<tr>
<td>perphenazine</td>
<td>292</td>
</tr>
<tr>
<td>phenelzine</td>
<td>8, 113, 186, 323–4, 410</td>
</tr>
<tr>
<td>phenetermine</td>
<td>10, 344–5</td>
</tr>
<tr>
<td>phenylephrine</td>
<td>10</td>
</tr>
<tr>
<td>phenylpropanolamine</td>
<td>10</td>
</tr>
<tr>
<td>phenytoin</td>
<td>238</td>
</tr>
<tr>
<td>pimozone</td>
<td>180</td>
</tr>
<tr>
<td>pindolol</td>
<td>42</td>
</tr>
<tr>
<td>piroxicam</td>
<td>95–6</td>
</tr>
<tr>
<td>pramipexole</td>
<td>48–9, 50–1, 442–3</td>
</tr>
<tr>
<td>pramlintide</td>
<td>344–5</td>
</tr>
<tr>
<td>prazosin</td>
<td>95–6, 102</td>
</tr>
<tr>
<td>prilosec</td>
<td>410</td>
</tr>
<tr>
<td>Prolixin (fluphenazine)</td>
<td>210</td>
</tr>
<tr>
<td>propranolol</td>
<td>238, 345–7</td>
</tr>
<tr>
<td>protriptyline</td>
<td>410</td>
</tr>
<tr>
<td>Provigil (modafinil)</td>
<td>171, 189, 190, 227–31, 238, 262–4, 410, 420–2, 424–6, 439–40</td>
</tr>
<tr>
<td>pseudoephedrine</td>
<td>10</td>
</tr>
<tr>
<td>rasagiline</td>
<td>8, 113</td>
</tr>
<tr>
<td>Razadyne (galantamine)</td>
<td>213–14</td>
</tr>
<tr>
<td>Rimeron (mirtazapine)</td>
<td>5, 6, 42, 53–5, 66–7, 102, 109, 171, 262–4, 293–300, 317–18, 323–4, 328, 410</td>
</tr>
<tr>
<td>Remicade (infliximab)</td>
<td>71, 423</td>
</tr>
<tr>
<td>Revia (naltrexone oral)</td>
<td>244–5, 248, 250</td>
</tr>
<tr>
<td>riluzole</td>
<td>42, 352–5, 442–3</td>
</tr>
<tr>
<td>Ritalin (methylphenidate)</td>
<td>10, 48–9, 50, 53–5, 70–5, 136–40, 160, 168–9, 229, 244–6, 387</td>
</tr>
<tr>
<td>rosiglitazone maleate</td>
<td>35, 37–8</td>
</tr>
</tbody>
</table>
### Index of Drug Names

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>selegiline</td>
<td>8, 27, 29, 53–5, 111, 113</td>
</tr>
<tr>
<td>selegiline oral</td>
<td>8, 27</td>
</tr>
<tr>
<td>Serzone (nefazodone)</td>
<td>210, 262–4, 292</td>
</tr>
<tr>
<td>sodium oxybate</td>
<td>48–9, 50–1</td>
</tr>
<tr>
<td>sodium oxybate/gamma hydroxybutyrate</td>
<td>420–1</td>
</tr>
<tr>
<td>Strattera (atomoxetine)</td>
<td>138–9, 156–8, 227, 229–31, 245–7, 388, 393, 419–20</td>
</tr>
<tr>
<td>sulpiride</td>
<td>418, 425–7</td>
</tr>
<tr>
<td>Symbyax (olanzapine–fluoxetine combination)</td>
<td>246–7</td>
</tr>
<tr>
<td>Symmetrel (amantadine)</td>
<td>317–18</td>
</tr>
<tr>
<td>synthroid</td>
<td>419</td>
</tr>
<tr>
<td>T3</td>
<td>292</td>
</tr>
<tr>
<td>Tagamet (cimetidine)</td>
<td>257–8</td>
</tr>
<tr>
<td>Taxol</td>
<td>223–4</td>
</tr>
<tr>
<td>Tegretol (carbamazepine)</td>
<td>10, 18–19, 108, 258–9, 293–4, 342, 344–8, 452</td>
</tr>
<tr>
<td>temazepam</td>
<td>345–7</td>
</tr>
<tr>
<td>testosterone cream</td>
<td>424–5</td>
</tr>
<tr>
<td>tetrahydrocannabinol (THC)</td>
<td>426–7</td>
</tr>
<tr>
<td>thiothixene</td>
<td>210</td>
</tr>
<tr>
<td>thyroid</td>
<td>323–4, 424–6, 439–40</td>
</tr>
<tr>
<td>Topamax (topiramate)</td>
<td>42, 95–6, 102, 108, 176, 189, 209–10, 212, 217, 220–1, 238, 260–4, 293–4, 344–7, 452</td>
</tr>
<tr>
<td>tramadol</td>
<td>10</td>
</tr>
<tr>
<td>tranylcypromine</td>
<td>8, 112, 113, 186</td>
</tr>
<tr>
<td>trazodone</td>
<td>102, 106, 109, 111, 171, 293–4, 317–18, 421–3</td>
</tr>
<tr>
<td>trihexyphenidyl</td>
<td>35, 37–8</td>
</tr>
<tr>
<td>Trilafon (perphenazine)</td>
<td>292</td>
</tr>
<tr>
<td>Tremept (oxcarbazepine)</td>
<td>70–1, 108, 293–4, 344, 347–5, 342, 345–7</td>
</tr>
<tr>
<td>Vialum (diazepam)</td>
<td>117–27</td>
</tr>
<tr>
<td>valproate</td>
<td>15, 18–19, 22, 29, 70–1, 85, 95, 95–6, 209–10, 212, 214–15, 220–1, 229, 258–64, 363–6, 373, 410, 452, 457–8</td>
</tr>
<tr>
<td>valproate ER</td>
<td>17</td>
</tr>
<tr>
<td>venlafaxine</td>
<td>42, 44, 95–6, 108, 186, 189, 190, 201–2, 204, 242–4, 295–9, 323–4, 328–30, 410</td>
</tr>
<tr>
<td>venlafaxine + mirtazapine (California rocket fuel)</td>
<td>300, 326, 328</td>
</tr>
<tr>
<td>verapamil</td>
<td>70–1</td>
</tr>
<tr>
<td>Vicodin (hydrocodone + acetaminophen)</td>
<td>95–6, 242</td>
</tr>
<tr>
<td>Vivanex (lisdexamfetamine)</td>
<td>138–41, 156–8</td>
</tr>
<tr>
<td>Wellbutrin XL (bupropion XL)</td>
<td>35, 48–9, 51, 53–5, 66–7, 172, 342</td>
</tr>
<tr>
<td>Xanax (alprazolam)</td>
<td>1, 47, 292, 294–9, 316, 328, 406, 425–6</td>
</tr>
<tr>
<td>Xyrem (sodium oxybate)</td>
<td>48–9, 50–1</td>
</tr>
<tr>
<td>Xyrem (sodium oxybate/gamma hydroxybutyrate)</td>
<td>420–1</td>
</tr>
<tr>
<td>Zetia</td>
<td>419</td>
</tr>
<tr>
<td>Zoloft (sertraline)</td>
<td>1–4, 6, 17, 33, 42, 44, 102, 105, 201–2, 244–7, 342, 352–3, 394, 401</td>
</tr>
</tbody>
</table>
### Index of Drug Names

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>zonisamide</td>
<td>108, 293–4, 344–5, 347–8</td>
</tr>
<tr>
<td>Zyrtec (citirizine)</td>
<td>95–6</td>
</tr>
</tbody>
</table>
Index of Case Studies

Note: page numbers in italics refer to figures and tables

acceptance and commitment therapy (ACT) 101
acoustic neuroma 263
acute stress disorder, PTSD differential diagnosis 381
adiposis dolorosa see Dercum’s disease affect, inappropriate 440–1
affective disorder 86–7
classical discontinuity hypothesis 125
symptoms 88
treatment 87
see also schizoaffective disorder
aggressive behavior
Alzheimer’s disease 25–31
conduct disorder 145
oppositional defiant disorder 145
pediatric mania 271, 273
schizophrenia and Alzheimer’s disease 457
alcohol abuse 2
abstinence goal 251
ADHD
symptoms 243–4
treatment 245
anxiety 246–7
and depression 47
arson 309
denial 243–4, 247–8
with depression 241–55
and anxiety 47
followup 242–7
history 241–2
outcome 242–7
patient intake 242
driving under the influence 243
electroconvulsive therapy 246–7
goals of treatment 251
heavy drinking 249–50
lack of insight 247–8
lying about use 243
military service 93–5, 96

psychotherapy 244–5
psychotic depression 259
psychotic sex offender 451–2
reduced risk drinking 241, 249–50, 252
rehabilitation 243–4
relapse 246–7, 309
treatment-resistant depression 409–11
Alcoholics Anonymous (AA) 243–7
Alzheimer’s disease 28–9
aggressive behavior 25–31
antipsychotic drug treatment 457–9
atypical antipsychotics 25, 27–8, 30
cardiovascular disease risk 26–8, 457–9
elderly man with schizophrenia 457–60
history 457–8
outcome 458
patient intake 457
history 25–7
management 28–9
amphetamine
with MAO inhibitors 113
positive urine screen 105–16
anorexia nervosa 65
anti-parkinsonian drugs with antidepressants 315–22
anti-tumor necrosis factor (TNF) drugs 423
anticholinesterase inhibitors 325–7
anticonvulsant drugs
chronic mental illness 237, 239
mood stabilizing 441–3
antidepressant drugs 1
aggressive 300–1
with anti-parkinsonian drugs 315–22
antihypertensive treatment combination 105–16
anxiety disorder treatment in children 351–62
bipolar disorder 374
response 446
brain change attenuation 301, 333

© in this web service Cambridge University Press
www.cambridge.org
Index of Case Studies

antidepressant drugs (cont.)
 indefinite 4, 11
 low blood levels 323, 338
 Parkinson’s disease with depression 318
 personality disorder 441–3
 schizophrenia prodrome treatment 395
 treatment-resistant depression 323–4
 heroic dosing 329–30
 antipsychotic drugs
 Alzheimer’s disease patients 457, 459
 cardiovascular disease risk 26, 27–8, 457–9
 atypical
 augmentation 409–16
 complications with diabetes 411–12
 contraindication in diabetes 409, 415
 personality disorder 441–3
 prescribing in children 357–8
 social and cognitive decline 393–4
 cholinesterase inhibitor combination 457, 459
 chronic mental illness 237, 239
 D2 receptor occupancy 220–1
 heroic off-label drug use 311–12
 obesity 213–19
 pregnancy 343–4
 response 266
 schizophrenia prodrome treatment 395
 second generation atypical 285–6
 sexual disorders 453–4
 typical 347–8
 antisocial personality disorder 238–9, 451–4
 anxiety/anxiety disorder
 alcohol abuse 246–7
 behavioral desensitization 205–6
 benzodiazepines 405
 in children 351–62
 children 351–62
 outcome and followup 353–7
 polymorphic disabling 357
 SSRI prescribing 352–3
 treatment for normal development 358
 cognitive behavioral therapy 201–2, 204
 comorbid ADHD 151, 159
 deep brain stimulation 52–3
 diagnosis 352
 ECT 52
 elderly woman 291–2
 followup 204–6
generalized anxiety disorder 154, 159, 359
 history 47–8, 351
 insomnia 51
 investigations 50
 medications 201–8
 with narcolepsy 47–64
 outcome 204–6
 patient intake 352
 psychiatric evaluation 49, 51, 202, 204,
 severe generalized 49
 side effects of medications 201
 transcranial magnetic stimulation 52
 treatment-resistant depression 1–2, 4
 vagal nerve stimulation 52, 55–6
 anxiolytics, schizophrenia prodrome treatment 395
 apathy, SSRI-induced 65–7
 asperger’s syndrome 83–4, 392, 394
 attention deficit hyperactivity disorder (ADHD) 151–65
 adults
 rating scales 161–2
 screening 163
 alcohol abuse 243–5
 cognitive behavioral therapy 136, 156, 159
 comorbid anxiety 151, 159
 comorbid oppositional defiant disorder 141, 148, 151
 diagnosis 135, 160
 followup 155–9
 paediatrician 134–9
 psychiatric 140–1
 genetic contribution 160, 164
 girls 133–49
 history 133, 151–2
 inattentive type 141, 273
 insomnia 137, 139
 misdiagnosis 394
 with oppositional symptoms 147–8
 outcome 155–9
 paediatrician evaluation 134
 pediatric mania 271, 274
 prefrontal cortex 146–8

© in this web service Cambridge University Press  www.cambridge.org
Index of Case Studies

- psychiatric evaluation 139–40, 154
- rating scales 142–4
  - adult 161–2
- screening of adults 163
- sculpted therapy 142
- sleep hygiene 137
- social and cognitive decline 387, 389
- stimulants 151, 160, 164
- symptom checklist 161–2
- vacations 155–6
- atypical antipsychotics
  - Alzheimer’s disease 25, 27–8, 30
  - SSRI augmentation 33, 44
- autism 81–4
- phenotype 394
- back injury, military service 93–104
- back pain, low 417–18, 420–1
- behavioral desensitization, anxiety disorder 205–6
- behavioral inhibition, children 359
- behavioral therapy, outpatient 34
- Bell’s palsy 263
- benzodiazepines
  - anxiety disorder treatment 405
  - in children 351–62
  - augmentation of antipsychotics 309–10
  - clozapine in psychosis 218–21
  - dyskinesia with schizophrenia 282–3
  - efficacy 358
  - panic attacks with depression 401–3
  - high-dose 404–5
  - panic disorder 406
  - paranoid schizophrenia 310
- prescribing to children 335–6, 351–62
- dosage 361
- treatment-resistant psychosis 312
- biofeedback, chronic pain 420
- bipolar disorder 16, 73, 79, 117–27, 185
- antidepressants 374
- childhood-onset 81–91
- depression with hypertension 107
- diagnosis 120–2
- dichotomous disease model 124
- family history 352–3
- followup 85–6
- forecasting 81–91
- history 363–4, 446
- with hypomania 374
- identifying 446
- investigations 84
- mixed state 292–3
- mood instability 442–3
- mood stabilizer discontinuation 363–76
- not otherwise specified (NOS) 185, 190, 198
- personality disorder symptom overlap 447
- progression 196
- psychiatric evaluation 83–5, 364–5
- psychotherapy 85–6
- response to antidepressants 446
- single disease continuum model 125
- substance-induced mood disorder 375–6
- subtypes 192
- symptoms 79, 445
- treatment-resistant 442
- unipolar depression differential diagnosis 197
- bipolar I disorder 185, 198
- complaint 341
- diagnosis 119
- followup 344–8
- history 341–3
- outcome 344–8
- treatment history 342
- treatment-resistant mania 348–9
- bipolar I1/2 disorder 192
- bipolar II disorder 185, 198, 258
- bipolar II1/2 disorder 187–8, 193
- bipolar III disorder 187–8, 193
- bipolar III1/2 disorder 194
- bipolar IV disorder 194
- bipolar V disorder 195
- bipolar VI disorder 195
- bipolar spectrum 192, 444
- bipolar spectrum disorder 258, 265
- birth control pills 438–40
- bladder cancer 363–4
- brain changes
  - in chronic pain 430
  - in depression 301, 333
- breast cancer, cognitive dysfunction following chemotherapy 223–36
- breastfeeding, contraindication 345–7
- cancer
  - depressive episode 363

© in this web service Cambridge University Press

www.cambridge.org
Index of Case Studies

cancer (cont.)
panic in cancer survivor 401–7
recurrent depression in elderly patient 296–8
cannabis see marijuana
Capgras syndrome 211, 215–16
cardiovascular disease
antipsychotic drugs in Alzheimer’s disease 26–8, 457–9
depression 1–4, 5
risk
with clozapine 214–15, 218–19
with mood stabilizers 374
with pimozide 180
with valproate 364–5
with venlafaxine 328, 330
transcranial magnetic stimulation 264, 267
catatonic, diagnostic measures 61
catechol-O-methyl transferase (COMT) 391, 398, 399
chaos 237–40
chemobrain 223–36
controversial concept 227–8, 233–4
definition 232
diagnosis 224
executive dysfunction 231
followup 224
incidence 230–1
investigations 224
psychiatric evaluation 223–4
specific cognitive defects 232
chemotherapy for breast cancer, cognitive dysfunction 223–36
childhood-onset disorders 81–91
followup 85–6
history 81–2
investigations 84
psychiatric evaluation 83–5
psychotherapy 85–6
children
anxiety disorder treatment 351–62
atypical antipsychotic drug prescribing 357–8
behavioral inhibition 359
benzodiazepine prescribing 335–6, 353, 357–8
dosage 361
generalized anxiety disorder 359
 pediatric mania 271–5
separation anxiety disorder 360
SSRI prescribing 352–3, 357–8
suicide monitoring 354, 357–8
see also attention deficit hyperactivity disorder (ADHD)
cholinesterase inhibitors 457–8
combination with antipsychotics 457–9
classical discontinuity hypothesis 125
cognitive behavioral therapy (CBT) 18, 34, 404–5
ADHD 136, 156, 159
anxiety 201–2, 204
chronic pain 420
obsessive–compulsive disorder 36–41
post-traumatic stress disorder 99
psychotic disorder 18–19
cognitive decline 387–400
diagnosis 392
followup 391–4
history 387–9
investigations 389–90
neurological evaluation/ neuropsychological testing 389–90
outcome 391–4
patient intake 390
psychiatric evaluation 391
cognitive dysfunction following chemotherapy for breast cancer see chemobrain
cognitive dysfunction following head injury 167–74
depression 168–9
followup 172
history 167–74
outcome 172
cognitive function, schizophrenia 387
cognitive restructuring therapy 100
colon cancer 297
combat experience, decompression 378
conduct disorder 133, 148
features 145
pediatric mania 274
confusion, psychotic depression 257–8, 261
continuous positive airway pressure (CPAP), obstructive sleep apnea 419
creatinine clearance, drug-induced renal changes 296–8
criminal responsibility, insanity 237, 309
Crohn’s disease 71
Index of Case Studies

cyclothymia with superimposed major depression 187–8

cyclothymic temperament 444

cytochrome P450 drug metabolizing enzymes 204, 327, 332, 338

daytime sleepiness 50–1, 59

deep brain stimulation (DBS) 38, 40–1, 326–7

anxiety 52–3

treatment-resistant depression 47, 62, 325–6, 413

delusional disorder

differential diagnosis 175–83

DSM IV 179

family members with schizophrenia 178

followup 177–8

history 175–6

ICD 10 179

outcome 177–8

psychiatric evaluation 176–7

delusions 175–83

psychosis 209–22

history 210–11

schizophrenia 283–4

substance abuse 209

dementia

early 292–3

treatment-resistant depression 325–6

depression

with alcohol abuse 241–55

followup 242–7

history 241–2

outcome 242–7

patient intake 242

asymptomatic recovery 302–3

brain changes 12, 301, 333

cognitive dysfunction following head injury 167–74

diabetes 409–10

double 187–8

followup 188–90

history 185–6, 187, 437–9

hypersomnia 51

hypertensive patient 105–16

outcome 109–11

psychiatric evaluation 105–16, 107, 109

indefinite treatment of recurrent 190

kindling hypothesis 304, 335–6

major 1–13, 47–8, 69–80, 196

with cyclothymia 187–8

cyclothymic 444

outcome prediction 334

progressive 305, 335–6

recurrent 190

relapse 306, 337

remission 305, 336–7

unipolar with anxiety 292–3

major depressive episodes 334–5

mood fluctuation 437–9

diagnosis 439–40

psychiatric evaluation 440–2

outcome 188–90

prediction 302–3, 334

parkinsonism fluctuation 320

Parkinson’s disease 316, 318

postpartum 2

progression 304

psychiatric evaluation 187–8

psychotic 257–70

followup 260–4

history 257–9

outcome 260–4

psychiatric evaluation 258

recurrent in elderly woman 291–307

contact reestablishment 298–9

diagnosis 292–3

followup 294–8

history 291–2

outcome 294–8, 302–3

psychiatric evaluation 293–4

quality of life 299

sustained remission 299

relapse

multiple 300

prevention 191

remission 301

residual symptoms 302–3, 334

schizoaffective disorder 15–16

suicide 16, 186

treatment 406, 410

treatment-resistant 1–13, 323–40

anxiety with narcolepsy 47–64

atypical antipsychotics 409–16

case debrief 6–7

experimental protocols 325–6

followup 328–30, 411–13

history 323–4, 409–10

initial psychiatric evaluation 4
Index of Case Studies

depression (cont.)
  treatment-resistant (cont.)
    interim followups 5–6
    investigations 325–6
    outcome 328–30, 411–13
    patient intake 410
    psychiatric evaluation 325–6, 410–11
    psychiatric history 1–4
    treatments 47, 62–3
  unipolar 185, 187–8, 440–1
    with anxiety 292–3
    bipolar depression differential diagnosis 197
    incidence 198
    major 49
    unstable 185–99
    vagal nerve stimulation 55–6
    see also bipolar disorder
  depressive recurrent unipolar disorders, major 49
  Dercum’s disease 417–21
  features 430
  diabetes
    atypical antipsychotic complications 411–12
    contraindication 409, 415
    clozapine side effect 212
    depression 409–10
    prediabetes complication of antipsychotics 217
    schizophrenia treatment risks 392
    valproate associated 363
    see also hyperglycemic hyperosmotic syndrome (HHS)
  diabetic ketoacidosis (DKA) 411–12, 414
  dichotomous disease model 124
  disability litigation 425–6
  dissociative states 440–1
  dopamine
    neurotransmission enhancement 167, 173–4
    overactivity 90
    sensivity 318–20
    dopamine D1 receptors, stimulation 274
    dopamine D2 receptors 130–1, 177–8
    blockade 218–19, 274, 279–80
    paranoid schizophrenia 310–11
    maladaptive effects of antipsychotics 286
  nigrostriatal pathway 287–8
  occupancy for antipsychotics 220–1
  driving under the influence 243
  drug dependence therapy, psychotic disorder 18–19
  drug metabolism, abnormal 204
  drug overdose, anxiety and depression 47
  dyskinesia 277–89
    with bupropion therapy 260
    dopamine agonist-induced 321
    finger 281
    history 277–9, 280
    neuropsychological evaluation 283–4
    outcome 283–4
    prodopaminergic agent-induced 321
    psychiatric evaluation 280–3
    tongue 318–19
    worsening 279–80
    see also tardive dyskinesia
dyslipidemia 16, 212
  complications of antipsychotics 217
  psychotic sex offender 452–3
  schizophrenia treatment risks 392
dystonia 284–5
  tardive 281, 284–6
  dopamine D2 receptor blockade 288
eating disorders, numbness 65
elderly patients
  falls 295–6
  recurrent depression 291–307
  schizophrenia with Alzheimer’s disease 457–60
electroconvulsive therapy (ECT)
  alcohol abuse 246–7
  anxiety 52
  aphasia 329–30
  bipolar I disorder 342
  delusions 210
  depression with diabetes 410
  psychotic depression 258–9, 262
  response to treatment 323–4
  schizoaffective disorder 212
  treatment-resistant depression 328
  electroencephalogram (EEG), referenced for treatment-resistant depression 325–6, 326
  epidural blocks, chronic pain 417–18
  Epworth Sleepiness Scale (ESS) 59
Index of Case Studies

executive dysfunction, chemobrain 231
exposure therapy, post-traumatic stress disorder 99
extrapyramidal symptoms acute 286
drug induced 278–86 reversible 285–6
eye movement desensitization and reprocessing 100
falls, elderly patient 295–6
fibromyalgia 419–21, 430
fluctuating illness 88
forensic patients arson 309 elderly man with schizophrenia and Alzheimer’s disease 457 psychosis 129, 237 psychotic sex offender 452
gambling, internet 246–7
gastroesophageal reflux disease (GERD) 169 generalized anxiety disorder (GAD) 154 child 359 comorbid ADHD 159 comorbid obsessive–compulsive disorder 352–3 genetic testing depression 331 Huntington’s disease 281 schizophrenia 83–4, 87–8, 391, 395 genotyping, treatment-resistant depression 327, 332

Glasgow Coma Scale 382

glutamate, treatment-resistant depression 333 grandiosity, psychotic sex offender 451–5
Gurdjieff, George 424–5
hallucinations 175, 181 auditory 237, 309, 452–3 command 237
psychotic depression 261–2
head injury, cognitive dysfunction 167–74 heavy drinking 249–50 see also alcohol abuse herbal remedies 424–5
hip fracture, elderly patient 295–6 histrionic personality disorder 71, 79, 440–1 homicide 129

Huntington’s disease 281, 283–5 hypercholesterolemia, chronic pain patient 418–19 hyperglycemic hyperosmotic syndrome (HHS) 411–13 warning signs/symptoms 414 hypersonia 51 diagnostic measures 61 primary 60 hypertension contraindications 116 depression treatment 105–16 MAOIs 112 potentially lethal combos 10, 114 hyperthermia, MAOI potentially lethal combos 10, 114 hypomania 368–74 bipolar disorder 374

ideas of reference 237, 309 immunosuppressants 424–5 impulsivity 238–9 insanity, criminal responsibility 237, 309 insomnia ADHD 137, 139 anxiety 51 cognitive dysfunction following head injury 172 mania 347–8, 366–7 Parkinson’s disease 316

International Classification of Sleep Disorders 57

jail sentence, driving under the influence 243

Kabat-Zinn, Jon 424–5 kindling hypothesis 304, 335–6 Kraepelinian model 124 Kraepelinian outcome 81–91

Landau Kleffner syndrome 388–9 laxatives, abuse 65 learning disability 389–90 social and cognitive decline 389 leg pain 417–18, 420–1 Lewy body dementia 29

lipomas, multiple painful subcutaneous 417, 419–21, 430 low back pain 417–18, 420–1

473
Index of Case Studies

lumbar disc disease, degenerative 417–21
lung cancer 298

major depressive episodes (MDEs) 334–5
mania
adult onset 271, 275
antidepressant-induced 363–76
followup 344–8
insomnia 347–8
management 341–3
outcome 344–8
pediatric 271–5
diagnosis 273
history 271–2
psychiatric evaluation 272–4
persistence 345–7
postpartum
recurrence risk 345
treatment 345–7

pregnancy 343–4
prevention 443
psychiatric evaluation 364–5
psychotic break 118
psychotic depression 257–8, 261
psychotic sex offender 451–5
recurrence 367–9
treatment history 342

treatment-resistant 348–9

marijuana
depression with mood fluctuations 439–40
medical 426–7
psychotic disorder 17–18, 21–2
memory loss see chemobrain
meningitis 389–90
mental illness, chronic 237–40
outcome 238
mentally disordered offender, psychotic sex offender 452
methylenetetrahydrofolate reductase (MTHFR) 391, 399

military service 93–104
history 93–5
psychiatric disorder incidence 93
psychiatric evaluation 95–7
psychological risk 97–8
traumatic brain injury 377–85
monoamine oxidase (MAO) enzymes 8, 113
monoamine oxidase inhibitors (MAOIs) 7–11
with amphetamine actions 8, 113
with amphetamines 113
approved 8, 113
depression with diabetes 410
hypertension 112, 116
potentially lethal combos 10, 114
treatment-resistant depression 63
tyramine dietary modifications 8, 114
mood disorder 69–80, 437–49
mixed psychotic disorder 453–4
outcome 77
personality disorder
comparison 79, 447
differential diagnosis 79
prevalence 196, 445
psychiatric evaluation 72–4
substance-induced 374–6
symptoms 79, 81
mood instability 440–1, 443
mood stabilizers
 cardiovascular disease risk 374
discontinuation 363–76
mania treatment 364
obesity 341–9
motivational interviewing 101

movement disorders
drug-induced 277, 280–3
Parkinson’s disease 321
permanent 284–5
presymptomatic 320
primary 320
rapid onset 285–6
see also dyskinesia; dystonia; tardive dyskinesia
mTOR pathway 333

multiple medical conditions
chronic pain patient 417–35
recurrent depression 299–301

multiple sleep latency test 57–8, 61

narcissistic personality disorder 71, 79

narcolepsy 47–64
classification 57
diagnostic measures 61
features 57–8
investigations 50

neuropsychological functioning, ultra high risk of psychosis 89

neurostimulation therapies see deep brain stimulation (DBS); electroconvulsive

474
Index of Case Studies

therapy (ECT); transcranial magnetic stimulation (TMS); vagal nerve stimulation (VNS)
nigrostriatal pathway 286–8
non-Hodgkin’s lymphoma 401, 405
noncompliance, drug blood levels 338
norepinephrine 9
neurotransmission enhancement 167, 173–4
numbness 65–7
eating disorders/substance abuse 65
nutritional supplements 424–5

obesity 16
chronic pain patient 418–19
clozapine side effect 212–19
mood stabilizers 341–9, 366–7
psychotic sex offender 452–3
obsessive–compulsive disorder (OCD) 33–45
cognitive behavioral therapy 38–41
comorbid delusional disorder 178
comorbid generalized anxiety disorder 352–3
deep brain stimulation 38, 40–1
delusional disorder differential diagnosis 180
differential diagnosis 175–83
evidence-based treatments 33, 44
history 33–5
initial evaluation 36
outcome 37–40
serotonergic antidepressants 41, 42–3
severity improvement 43
social and cognitive decline 387
obstructive sleep apnea 57, 61, 167
chronic pain patient 418–20
CPAP use 419
oculogyric crisis 279, 288
omega 3 fatty acids, schizophrenia prodrome treatment 395
opiates
avoidance of real issues 427–8
chronic pain treatment 417–35
dependence 422–3, 428
detoxification program 421–2, 426–7
dosage 420
escalating 427–8
reduction 422–3, 425–6

overdose 422–3, 427
somatoform disorders 428
oppositional behavior 271
oppositional defiant disorder 133, 273–4
comorbid ADHD 141, 148, 151
diagnosis 135
features 145
psychiatric evaluation 139–40
oppositional symptoms 133
with ADHD 147–8, 148
history 133
paediatrician evaluation 134

oral contraceptives see birth control pills
P450 drug metabolizing system see cytochrome P450 drug metabolizing enzymes
pain, chronic 417–35
brain changes 430
cause 417, 430
epidural blocks 417–18
followup 420–7
history 417–19
leg 417–18
lipomas 417
low back 417–18
outcome 420–7
patient intake 417
psychiatric evaluation 419
pain disorder 419–20
somatoform 419, 429
panic attacks
cancer survivor 401–7
followup 403–5
history 401–2
outcome 403–5
patient intake 402
psychiatric evaluation 402
panic disorder, benzodiazepines 406
paraphilia 453–4
parkinsonism 315–22
antipsychotic-induced 291, 293–8, 300
reversal 306
atypical 317
falls 295–6
fluctuation with depression 320
psychomotor retardation 318–19
reversible 320
Index of Case Studies

Parkinson’s disease 292–8, 315–22
  depression 318
  falls 295–6
  followup 316
  outcome 316
  psychiatric evaluation 316
  periodic limb movements 57
  see also restless legs syndrome
  persecutory ideation 237, 309
  persistent post-concussive syndrome (PPCS) 383
  PTSD differential diagnosis 377, 384
  traumatic brain injury overlap 384
personality disorder 69–80, 437–49
  diagnosis 439–40
  mood disorder
    comparison 79, 447
    differential diagnosis 79
    mood symptoms 437, 447
    outcome 77
    polymorphic mixed 440–1
    prognosis 441
    psychiatric evaluation 72–4
    symptoms 79
  pervasive developmental disorder 394
  pharmacodynamic/pharmacokinetic failure 338
  phenotyping, treatment-resistant depression 327
  pituitary adenoma 421–2
polypharmacy 239
polysubstance abuse 237
post-concussive syndrome 377–85
  PTSD differential diagnosis 377, 384
  post-traumatic stress disorder (PTSD) 238–9, 377–85
  acute stress disorder differential diagnosis 381
  military service 90
  post-concussive syndrome differential diagnosis 377, 384
  premorbid childhood onset 237
  psychopharmacologic options 102
  psychotherapy options 98–101
  risk 97–8
  traumatic brain injury co-occurrence 383
  postpartum depression 2

postpartum period 345
  mania treatment 345–7
  prediabetes, complications of antipsychotics 217
  prefrontal cortex
  ADHD 146–8
  head injury 173
  pregnancy
  antipsychotic drugs 343–4
  mania 343–4
  prodomes 90
  psychoanalysis 72
  psychomotor retardation 318–20
  psychosis 117–27
    behavioral control in uncooperative patient 309–13
    classical discontinuity hypothesis 125
    delusions 209–22
    depression 257–70
    dichotomous disease model 124
    dyskinesia 277–9
    long-term 237, 238
    malignant 130–1
    mood disorder 453–4
    neurocognitive deficits 89
    outcome 212
    partial symptom control on clozapine 129–32
    patient intake 211
    prodomes 90
    psychiatric evaluation 212
    sex offender 451–5
    followup 452–3
    history 452
    outcome 452–3
    patient intake 451–2
    single disease continuum model 125
    substance abuse 209
    treatment-resistant 209–22, 309, 312, 451, 454
    ultra high risk 89, 392, 396
psychotherapy
  ADHD 139–40
  alcohol abuse 244–5
  bipolar disorder 85–6
  childhood-onset disorders 85–6
  chronic pain 422–3, 426–7
  insight oriented 420
  mood disorder 72
Index of Case Studies

mood instability 443
opiate dependence 422–3
oppositional defiant disorder 139–40
personality disorder 441–3
post-traumatic stress disorder 98–101
refusal by alcoholic 243–4
schizophrenia 85–6
psychotic disorder spectrum, symptoms 81
psychotic illness 15–23
case debrief 18
followup visits 18–19
history 15–16
negative symptoms 20–1
patient intake 16
quality of life, recurrent depression in elderly woman 299
rapamycin (mTOR) pathway 333
reduced risk drinking 241, 249–50, 252
rehabilitation, alcohol abuse 243–4
restless legs syndrome 50–1, 57, 316
diagnostic features 60
with obstructive sleep apnea 167
rheumatoid arthritis 421–5
schizoaffective disorder 15–16, 117–27
bipolar type 451–2
classical discontinuity hypothesis 125
diagnosis 119–23
dichotomous disease model 124
followup 121
long-term 237
outcome 121, 212
single disease continuum model 125
substance abuse 212
treatment 120
treatment resistant 118
unremitting psychosis 118
schizoid personality disorder 394
schizophrenia 15–16, 117–27
childhood-onset 81–81
classical discontinuity hypothesis 125
clinical course 397
cognitive function 387, 399
diagnosis 119–22
dichotomous disease model 124
differential diagnosis 175–83
disorganized type 129
dyskinesia 278, 280–3
elderly man with Alzheimer’s disease 457–60
history 457–8
outcome 458
patient intake 457
executive functioning 399
family members 178
followup 85–6
forecasting 81–91
genetics 391, 396
history 129–30
investigations 84
neurocognitive deficits 89
neurodegenerative basis 397
outcome 130, 283–4
paranoid 309
followup 310–11
heroin off-label drug use 311–12
history 310
outcome 310–11
followup 310, 312
prodrome 90, 391–4
treatment 392, 394–5
psychiatric evaluation 83–4, 85
psychotherapy 85–6
psychotic break 117
risks of treatment 392
single disease continuum model 125
susceptibility genes 396
treatment 120
schizotypal personality disorder 179–81
sedation, schizophrenia treatment risks 392
seeking safety therapy 101
selective serotonin reuptake inhibitors (SSRIs)
apathy 65–7
chronic pain 418
depression with diabetes 410
efficacy 358
panic attacks with depression 401
prescribing to children 352–3, 357–8
suicide monitoring 354, 357–8
self mutilatory behavior 237–8, 437–40
personality disorder 440–1
separation anxiety disorder 360
serotonergic antidepressants, obsessive–compulsive disorder 41–3

© in this web service Cambridge University Press  www.cambridge.org
Index of Case Studies

serotonin syndrome, MAOI potentially lethal combos 10, 114
### Index of Case Studies

- **Incomplete recovery**: 169–71
- **Outcome**: 378–80
- **Persistent post-concussive syndrome**: 383–4
- **Psychiatric evaluation**: 378
- **PTSD**: 383
- **Post-concussive syndrome differential diagnosis**: 377, 384
- **Vestibular symptoms**: 378–80
- **Tyramine**: 8–9, 116
- **Dietary modifications**: 8, 114
- **Vagal nerve stimulation (VNS)**
  - **Anxiety**: 52, 55–6
- **Depression**: 55–6
- **Treatment-resistant depression**: 47, 62–3, 412
- **War zone, decompression**: 378
- **Weight gain**: 421–2
- **Chronic pain patient**: 421–2
- **Mood stabilizers**: 341–9, 366–7
- **Olanzapine**: 341–9
- **Schizophrenia treatment risks**: 392
- **Valproate associated**: 363
- **See also obesity**: 
  - **Weight loss, mood stabilizer regime modification**: 366–7
  - **Wrist pain, bilateral**: 421–3